Sign in
TARA Stock Price, Chart, Stats & News
Protara Therapeutics, Inc.
Save
Protara Therapeutics, Inc. (TARA) does not currently pay a dividend.
184.35M
Market cap
–
Current P/E
–
Forward P/E
TARA chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -27.42% |
ROE | -36.38% |
D/E | 0.02x |
Interest coverage ratio | -42.98x |
TARA valuation
P/E | – |
P/S | – |
P/B | 1.16x |
P/CF | -4.04x |
P/FCF | -3.38x |
P/OCF | -4.04x |
PEG | -0.57x |
EV multiple | -3.87x |
About
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations.
Similar securities
Based on sector and market capitalization
Report issue